Bacille Calmette-Guerin (BCG) is becoming the treatment of choice for superficial bladder tumors. Prospective randomized clinical trials have shown that the efficacy of intravesical BCG as an adjuvant to surgery is superior to surgery alone or adjuvant chemotherapy. The mechanisms by which BCG mediates antitumor activity are not well understood. Data from clinical trials on bladder cancer patients as well as studies on animal tumor models suggest that BCG-mediated modulation of immune responsiveness is closely associated with efficacy; however, the active components remain an enigma. A better understanding of the mechanisms of action of BCG may lead to the developement of prognostic indicators and more effective therapeutic regimens. To this end a mouse bladder tumor model in which tumors are implanted directly into bladders has been adapted for the study of intravesical BCG therapy. Using this model, recent developments in monoclonal antibodies to cell surface differentiation antigens, flow cytometry techniques and immunomodulatory techniques will be utilized to determine BCG-mediated antitumor mechanisms. During BCG therapy, the responding lymphoid cells in the bladder, regional lymph nodes and spleens will be identified by flow cytometry analysis of appropriately labelled cells. These cells will then be isolated and functional capacities will be determined. The same process will be repeated with animals compromised immunologically by alteration of T cells, macrophage or natural killer cell responsiveness. Adoptive transfer of specific lymphoid subpopulations will be performed to verify the role of lymphoid cells in BCG-mediated antitumor activity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA037926-02
Application #
3175876
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1984-05-01
Project End
1987-04-30
Budget Start
1985-05-01
Budget End
1986-04-30
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Barnes-Jewish Hospital
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63110
Kuroda, K; Brown, E J; Telle, W B et al. (1993) Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 91:69-76
Ratliff, T L; McCarthy, R; Telle, W B et al. (1993) Purification of a mycobacterial adhesin for fibronectin. Infect Immun 61:1889-94
Ratliff, T L; Ritchey, J K; Yuan, J J et al. (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150:1018-23
Hudson, M A; Brown, E J; Ritchey, J K et al. (1991) Modulation of fibronectin-mediated Bacillus Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 51:3726-32
Becich, M J; Carroll, S; Ratliff, T L (1991) Internalization of bacille Calmette-Guerin by bladder tumor cells. J Urol 145:1316-24
Hudson, M A; Yuan, J J; Catalona, W J et al. (1990) Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol 144:1362-4
Kavoussi, L R; Brown, E J; Ritchey, J K et al. (1990) Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85:62-7
Hudson, M A; Ritchey, J K; Catalona, W J et al. (1990) Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res 50:3843-7
Mikkelsen, D J; Ratliff, T L (1989) Mechanisms of action of intravesical bacillus Calmette-Guerin for bladder cancer. Cancer Treat Res 46:195-211
Aslanzadeh, J; Brown, E J; Quillin, S P et al. (1989) Characterization of soluble fibronectin binding to Bacille Calmette-Guerin. J Gen Microbiol 135:2735-41

Showing the most recent 10 out of 18 publications